Thus, absorbed doses in tumor lesions were found to be therapeutically relevant, whereas rapid clearance from normal GRPR-rich organs was confirmed, such as the pancreas, considered to be the dose-limiting organ due to its high radioligand uptake [37]. This evidence concerns the gene GRPR and neoplasm.